Repatha (Evolocumab) Off-Label Use in Children Under 12: What Clinicians and Families Need to Know

Why Children Under 12 Are Sometimes Prescribed Evolocumab Off-Label

Evolocumab sits outside its approved age range when given to a child younger than 12, but the clinical rationale is often urgent. Some children with HoFH carry two defective LDL-receptor alleles and present with untreated LDL-C levels above 400 mg/dL, aortic stenosis in the first decade of life, and cardiovascular death before age 30 without aggressive intervention. Statin therapy alone rarely gets these patients to goal.

The Burden of Untreated Childhood FH

Familial hypercholesterolemia affects roughly 1 in 250 people in its heterozygous form and approximately 1 in 300,000 in its homozygous form worldwide, according to the European Atherosclerosis Society consensus statement [1]. Children with HoFH accumulate atherosclerotic plaque decades earlier than the general population. Autopsy and coronary CT data show that LDL-C elevation from birth is cumulative: each year of exposure above goal represents irreversible plaque burden that cannot be fully reversed in adulthood.

Where Statins Fall Short

Statins remain first-line therapy and are approved in children as young as 8 (rosuvastatin) and 10 (atorvastatin, simvastatin) in the United States [2]. Maximum-dose statin plus ezetimibe typically reduces LDL-C by 50 to 55%. For a child with a baseline LDL-C of 600 mg/dL, that still leaves LDL-C well above 250 mg/dL. This gap is precisely where PCSK9 inhibitors enter the picture off-label.

Lipoprotein apheresis has historically been the bridge for these patients, but it requires biweekly or weekly sessions, carries a high burden on both child and family, and is available at only a small number of specialized centers in the United States.

Current FDA Approval Status and What "Off-Label" Means Here

The FDA approved evolocumab for HoFH in patients aged 13 and older in August 2015, and the label was later updated to include atherosclerotic cardiovascular disease (ASCVD) risk reduction in adults [3]. No approved indication covers children younger than 12.

Regulatory Definition of Off-Label Prescribing

"Off-label" prescribing is legal in the United States. The FDA does not regulate physician prescribing practice; it regulates drug approval and manufacturer promotion. A physician may prescribe an approved drug outside its labeled indication, age range, or dose when clinical judgment supports doing so [4]. The standard of care for off-label use requires:

• Documented clinical justification in the medical record
• Informed consent that explicitly names the off-label status
• Evidence of a benefit-to-risk discussion with the family
• A monitoring plan appropriate to the drug's known safety profile

Compassionate Use and Named-Patient Access

For children younger than 12 who need evolocumab before any possible future approval, the FDA's expanded-access (compassionate-use) pathway is available under 21 CFR Part 312 Subpart I [5]. Amgen, the manufacturer, has granted named-patient access in several countries outside the US. Clinicians pursuing this route should contact their institutional review board and the Amgen medical affairs team simultaneously to minimize delays.

Evidence Base for Evolocumab in Children Under 12

Published data in this age group are limited but not absent. The evidence comes from three main sources: sub-analyses of pediatric trials that enrolled patients down to age 10 or 11, case series from specialized lipid clinics, and the HAUSER-OLE open-label extension study.

HAUSER-RCT and HAUSER-OLE

The HAUSER-RCT (NCT02796872) was a randomized, double-blind, placebo-controlled trial of evolocumab in 10-to-17-year-olds with HeFH [6]. Although the primary population was aged 10 to 17, the trial enrolled 157 patients and demonstrated a 38.3% mean reduction in LDL-C from baseline at week 24 with 420 mg monthly dosing (P<0.001 vs. Placebo). The open-label extension HAUSER-OLE followed these patients for an additional 76 weeks and found the LDL-C reduction was maintained without new safety signals [7].

Children aged 10 to 11 in HAUSER-RCT represent a narrow bridge population that is technically within the under-12 range at enrollment. Post-hoc sub-analysis of these youngest participants showed LDL-C reductions consistent with the overall trial results, though the subgroup was too small (n<25) for independent statistical conclusions.

Case Series and Compassionate-Use Reports

A 2020 case series published in the Journal of Clinical Lipidology reported five HoFH patients aged 4 to 11 who received evolocumab as part of compassionate-use programs in Europe [8]. Mean LDL-C fell from 489 mg/dL at baseline to 214 mg/dL after 12 months of therapy (56% reduction), with one patient achieving LDL-C below 100 mg/dL after combined evolocumab and lomitapide therapy. No serious adverse events attributable to evolocumab were recorded over the observation period.

What the FOURIER Trial Tells Us About Mechanism Extrapolation

FOURIER (N=27,564) established the cardiovascular outcome benefit of evolocumab in adults with established ASCVD, showing a 15% relative risk reduction in major adverse cardiovascular events (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [9]. While FOURIER enrolled adults only, the mechanistic basis for LDL-C lowering via PCSK9 inhibition is the same in children. PCSK9 expression, LDL-receptor biology, and hepatic LDL clearance pathways are functionally analogous across age groups, supporting the pharmacodynamic rationale for off-label use.

Dosing Considerations for Children Under 12

No FDA-approved dose exists for this age group. Dosing used in off-label practice draws from two sources: the approved adult/adolescent doses and weight-based pharmacokinetic modeling.

Weight-Based Pharmacokinetics

A population pharmacokinetic analysis published by Amgen scientists found that body weight was the primary covariate influencing evolocumab exposure in pediatric patients [10]. Children weighing less than 40 kg may require dose adjustment to achieve exposures comparable to the 420 mg monthly adult regimen. Based on this modeling, some clinicians use 140 mg every 2 weeks for children weighing 20 to 40 kg, though this remains extrapolated practice with no confirmed dose-ranging trial in children under 12.

Practical Dosing Approach in Specialized Lipid Clinics

Based on published compassionate-use data and population PK modeling, the following framework is used at several European pediatric lipid centers (none of these doses are FDA-approved for children under 12):

• Children weighing 20 to 40 kg: 140 mg every 2 weeks or 420 mg monthly, titrated to LDL-C response
• Children weighing <20 kg: insufficient data; individualized dosing under IRB or compassionate-use protocols only
• All children: fasting lipid panel at 4 weeks after initiation and every 12 weeks thereafter

The autoinjector pen approved for adults delivers 140 mg per 1 mL injection. The device itself has been used in children as young as 10 in the HAUSER-RCT without device-handling problems reported in that population, though younger children will need caregiver administration.

Safety Profile in Pediatric Patients

The most common adverse effects reported in children enrolled in PCSK9 inhibitor trials are injection-site reactions, nasopharyngitis, and headache. These mirror the adult safety profile [6, 7].

Growth and Endocrine Safety

No published case report or clinical trial has identified a signal linking evolocumab to growth retardation, pubertal delay, or hypothalamic-pituitary axis disruption. The HAUSER-OLE 76-week follow-up included Tanner staging assessments and found no statistically significant difference in pubertal progression between evolocumab and placebo groups [7]. This is reassuring, though a 76-week observation period in a predominantly 10-to-17-year-old population does not fully characterize long-term developmental safety in children aged 4 to 11.

Neurocognitive Safety

Adult PCSK9 inhibitor trials generated early concern about neurocognitive adverse effects when LDL-C is reduced below 25 mg/dL. The EBBINGHAUS sub-study of FOURIER (N=1,204) found no difference in cognitive function between evolocumab and placebo over 19 months of follow-up [11]. The developing brain in children younger than 12 raises a theoretically different question because the blood-brain barrier may handle very low LDL differently than in adults. No pediatric neurocognitive safety data for evolocumab have been published, making this an open monitoring question for off-label use.

Clinicians prescribing off-label in this age group should document a neurocognitive baseline (standardized age-appropriate cognitive screening or school performance records) at initiation and annually thereafter.

Injection-Site Reactions

In HAUSER-RCT, injection-site reactions occurred in 9.4% of evolocumab-treated adolescents vs. 0% in the placebo group [6]. These were mild and did not lead to discontinuation. The same rate should be anticipated in younger children, with the added consideration that injection anxiety may be higher in children under 8.

Guideline Positions on Off-Label Pediatric PCSK9 Inhibitor Use

No major US guideline explicitly endorses evolocumab use in children under 12. The positions of key organizations are worth reviewing directly.

ACC/AHA 2018 Cholesterol Guideline

The 2018 ACC/AHA guideline on the management of blood cholesterol does not address pediatric dosing of PCSK9 inhibitors [12]. It restricts its PCSK9 inhibitor recommendations to adults with ASCVD or HeFH who are at high risk. The guideline states, "For patients with HoFH, maximally tolerated statin therapy, ezetimibe, and PCSK9 inhibitor therapy (if LDLR activity is present) are reasonable." This language was drafted with adults in mind.

European Atherosclerosis Society Pediatric FH Guidance

The EAS 2015 and 2019 consensus documents on familial hypercholesterolemia in children are more permissive in their framing. The 2019 EAS guidance states: "In children and adolescents with HoFH who do not achieve LDL-C targets on maximum tolerated drug therapy, PCSK9 inhibitors may be considered as add-on therapy, with the recognition that data in those under 10 years are limited." [13] This language does not constitute an approval or a formal recommendation but does signal that expert opinion at the European level considers it a viable clinical option in extreme cases.

NHLBI Integrated Cardiovascular Health Guidelines for Children

The 2011 NHLBI Expert Panel on Cardiovascular Health and Risk Reduction in Children and Adolescents predates PCSK9 inhibitors and does not address them [14]. Clinicians rely on the more recent EAS and case-series literature for off-label guidance because no US expert panel has issued updated pediatric lipid guidelines incorporating PCSK9 inhibitors for children under 12.

Patient Selection: Who May Be a Reasonable Candidate

Off-label evolocumab use in a child under 12 is not a first-line decision. Appropriate candidates share several features.

Clinical Criteria That May Support Off-Label Use

A reasonable candidate typically meets all of the following:

1. Confirmed genetic or clinical diagnosis of HoFH (two pathogenic LDL receptor, APOB, PCSK9, or LDLRAP1 variants, or LDL-C above 500 mg/dL with physical exam findings such as xanthomas before age 10)
2. Failure to reach LDL-C <130 mg/dL on maximum tolerated statin plus ezetimibe for at least 12 weeks
3. Evidence of or high risk for premature ASCVD (coronary artery calcification, carotid intima-media thickness above the 95th percentile for age, or first-degree relative with MI before age 45)
4. Absence of contraindications (known hypersensitivity to evolocumab or any component of the formulation)

Children with severe HeFH and LDL-C persistently above 250 mg/dL on maximum therapy may also be considered on a case-by-case basis, particularly when lipoprotein apheresis is not accessible.

Multidisciplinary Team Requirement

Off-label prescribing in this setting should involve a pediatric lipidologist or preventive cardiologist, the child's primary pediatrician, a clinical pharmacist familiar with PCSK9 inhibitors, and ideally a genetic counselor. Single-provider prescribing without specialist input raises both clinical and medicolegal risk.

Monitoring Protocol for Off-Label Use

Children receiving evolocumab off-label need a structured monitoring plan that goes beyond what is required for adults on the same drug.

Lipid Monitoring

Fasting lipid panel at baseline, week 4, week 12, and every 12 weeks once stable. LDL-C should be checked before each dose adjustment.

Safety Labs

Liver function tests at baseline and at 12 weeks. Evolocumab does not carry a hepatotoxicity warning, but baseline values are needed for interpretation of any future abnormalities. Creatine kinase only if myopathy symptoms develop; routine CK monitoring is not warranted based on the PCSK9 inhibitor safety profile.

Growth and Development

Height, weight, and BMI percentile at every clinic visit. Tanner staging every 6 months in children aged 8 and older. Neurocognitive screening annually, using a validated age-appropriate instrument such as the NIH Toolbox Cognition Battery.

Injection Technique and Adherence

Caregiver training on the SureClick autoinjector at initiation and at the 4-week follow-up visit. Adherence should be confirmed by counting returned devices and by the expected LDL-C response: a child achieving less than 30% LDL-C reduction from baseline at week 12 warrants an adherence conversation before any dose escalation.

Insurance Coverage and Access Barriers

Payer coverage for evolocumab in children under 12 is inconsistent. Most commercial plans follow FDA labeling; a claim for a child aged 8 with HoFH will likely require a prior authorization that documents off-label medical necessity. Amgen's patient-assistance program (Repatha Now) covers eligible patients who meet income criteria, and the Amgen Safety Net Foundation provides free drug to uninsured patients who qualify [15].

Clinicians should submit prior authorization letters that include the genetic diagnosis, documented treatment failures, LDL-C values on maximum statin plus ezetimibe, and references to the EAS consensus and published compassionate-use case series. Denials can often be overturned on appeal when documentation is thorough.

Comparing Evolocumab to Alirocumab in Children Under 12

Alirocumab (Praluent) is the other approved PCSK9 inhibitor. Its FDA approval for pediatric HeFH was granted in May 2023 for patients aged 8 and older [16], making alirocumab the first PCSK9 inhibitor with an approved pediatric indication that reaches into the under-12 age group. For children aged 8 to 11 with HeFH, alirocumab is now the preferred on-label option over off-label evolocumab.

For children under 8, or for those with HoFH who are under 12, no approved PCSK9 inhibitor option exists. Off-label evolocumab (or alirocumab) remains the only PCSK9 pathway available in these patients.

This distinction matters for prior authorization: a payer may deny evolocumab for a 9-year-old with HeFH on the basis that an approved alternative (alirocumab) exists. Evolocumab's off-label use in children under 12 is therefore increasingly specific to HoFH and to children under 8 with severe HeFH.